Systemic Sclerosis

 

Ninfetanib Improves and Stabilizes Lung Function in Systemic Sclerosis

November 18, 2019

Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize.

Riociguat for Systemic Sclerosis Digital Ulcers May Require Longer Treatment

September 12, 2019

A proof of concept clinical trial for riociguat (Adempas, Bayer) for patients with systemic sclerosis indicates that longer treatment periods may be necessary to heal digital ulcers. In this trial, the treatment wasn't effective in reducing the number of digital ulcers.